Patel Sushil, the Chief Executive Officer of Replimune Group, Inc., recently sold 49,026 shares of common stock. This transaction, which took place on November 16, 2026, was executed to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). Such actions are common among executives, especially when it comes to managing tax liabilities associated with stock compensation.
The sale was made in accordance with the irrevocable "sell to cover" provision outlined in the RSU award agreements. This means that the shares were sold automatically to meet tax obligations, rather than as a discretionary sale by Sushil. Following this transaction, Sushil retains ownership of 659,125 shares of Replimune's common stock.
Background
Replimune Group, Inc. is a company focused on developing innovative treatments in the life sciences sector, specifically under the classification of biological products (no diagnostic substances). The firm is incorporated in Delaware and operates out of Woburn, Massachusetts. As of the latest filings, Replimune has been actively engaging in the market with several disclosures, reflecting its commitment to transparency and regulatory compliance.
What the Filing Says
The recent filing, with accession number 0001104659-26-129853, details the sale of shares by Patel Sushil. The document states, "Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the vesting of the Reporting Person's Restricted Stock Units." Additionally, it specifies that the shares were sold at a weighted average price of $21.60, with individual transaction prices ranging from $21.59 to $21.60.
Impact
This transaction may affect various stakeholders, including Replimune's investors and employees. For investors, the sale signifies the management's ongoing engagement with the company's stock and its financial management strategies. Employees, particularly those with similar stock compensation plans, might view this as a standard practice in managing their own tax liabilities.
What's Next
The filing does not say what happens next.
Read Next
RRA&Z Holdings Disposes of 375,000 Shares of Stock
BridgeBio Pharma CFO Trimarchi Thomas Reports Stock Transaction
BridgeBio Pharma's Apuli Maricel Reports Stock Transaction
CFO Emily Luisa Hill sells shares to cover tax obligations
Uber Technologies reports insider stock transactions by CAO
Uber's Jill Hazelbaker Reports Stock Transactions in SEC Filing






